Opportunistic Infections

Phase 4 trials (2)

• sulfamethoxazole
• trimethoprim

Phase 3 trials (1)

• cd45-depleted allogenic peripheral blood stem cell

Phase 1 trials (1)

• cmv-specific t-cells

Other trials (2)

• albendazole
• praziquantel

Organization Involved with Phase 4 Indications (7)

• National Institute of Allergy and Infectious Diseases (NIAID)
• Kenya Medical Research Institute
• Stanford University
• University of Bergen
• Muhimbili University
• Western Norway Regional Health Authority
• Centers for Disease Control and Prevention (CDC)

Organization Involved with Phase 3 Indications (4)

• Federal Research Institute of Pediatric Hematology, Oncology and Immunology
• Mbarara University of Science and Technology
• University of Minnesota
• Infectious Disease Institute, Kampala, Uganda

Organization Involved with Phase 2 Indications (2)

• Agouron
• Shenzhen Geno-Immune Medical Institute

Organization Involved with Phase 1 Indications (2)

• Case Western Reserve University
• University of Wisconsin

Organization Involved with Other Experimental Indications (5)

• National Institutes of Health (NIH)
• National Institute for Medical Research, Tanzania
• Catholic University of Health and Allied Sciences
• Makerere University
• University of Cambridge